Biophagy initiates a collaboration with Dr. Karin High, UNM, to study its proprietary compounds in chronic neuropathic pain, in vivo. By jordan|2022-02-01T19:09:54+00:00February 1, 2022|2018-announcements|0 Comments Share This Story, Choose Your Platform! FacebookTwitterRedditLinkedInWhatsAppTelegramTumblrPinterestVkXingEmail About the Author: jordan Related Posts Biophagy is awarded a New Mexico Small Business Assistance (NMSBA) leverage grant with Sandia National Laboratories to lead a team of four companies (including Avisa Pharma, PureInfo Discovery, and Omphalos Biosciences) to investigate binding dynamics of several proprietary autophagy stimulants on cytoskeleton and lysosome movement. They will also study compound enhancement of antibiotic killing using M. bovis, in mouse macrophages. This is a surrogate assay for tuberculosis. Biophagy is awarded a New Mexico Small Business Assistance (NMSBA) leverage grant with Sandia National Laboratories to lead a team of four companies (including Avisa Pharma, PureInfo Discovery, and Omphalos Biosciences) to investigate binding dynamics of several proprietary autophagy stimulants on cytoskeleton and lysosome movement. They will also study compound enhancement of antibiotic killing using M. bovis, in mouse macrophages. This is a surrogate assay for tuberculosis. Leave A Comment Cancel replyComment Save my name, email, and website in this browser for the next time I comment.
Leave A Comment